Case Report
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. May 15, 2023; 15(5): 902-910
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.902
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Chest computed tomography before and after treatment with fruquintinib showed multiple metastases in both lungs. A-C: A baseline chest computed tomography (CT) scan before fruquintinib treatment on August 24, 2020; D-F: CT after fruquintinib treatment was given for 3 mo (November 30, 2020); G-I: CT after fruquintinib treatment was given for 8 mo (May 31, 2021); J-L: CT after fruquintinib treatment was given for 12 mo (August 31, 2021).
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Chest computed tomography before and after treatment with fruquintinib plus tegafur-gimeracil-oteracil potassium showed multiple metastases in both lungs. A-C: Computed tomography (CT) before fruquintinib plus tegafur-gimeracil-oteracil potassium (S-1) treatment (August 31, 2021); D-F: CT after fruquintinib plus S-1 treatment was given for 2 mo (November 1, 2021); G-I: CT after fruquintinib plus S-1 treatment was given for 10 mo (June 13, 2022); J-L: CT after fruquintinib plus S-1 treatment was given for 13.5 mo (October 12, 2022).
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Treatment timeline of the patient. mFOLFOX6: Oxaliplatin, leucovorin, and 5-FU; PFS: Progression-free survival; S1: Tegafur-gimeracil-oteracil potassium; XELOX: Oxaliplatin and capecitabine.